Recent Analysts’ Ratings Changes for Rapport Therapeutics (RAPP)

Several analysts have recently updated their ratings and price targets for Rapport Therapeutics (NASDAQ: RAPP):

• 11/7/2026 – Rapport Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 11/5/2026 – Rapport Therapeutics had its price target lowered by Wells Fargo & Company from $50.00 to $47.00. They now have an “overweight” rating on the stock.
• 11/5/2026 – Rapport Therapeutics had its price target lowered by UBS Group from $71.00 to $64.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Rapport Therapeutics had its price target lowered by Guggenheim from $70.00 to $66.00. They now have a “buy” rating on the stock.
• 11/4/2026 – Rapport Therapeutics was given a new $73.00 price target by Raymond James Financial.
• 10/21/2026 – Rapport Therapeutics had its price target lowered by Wells Fargo & Company from $51.00 to $50.00. They now have an “overweight” rating on the stock.
• 10/21/2026 – Rapport Therapeutics had its price target raised by JonesTrading from $50.00 to $82.00. They now have a “buy” rating on the stock.
• 10/20/2026 – Rapport Therapeutics had its “outperform” rating reaffirmed by Citigroup.
• 10/20/2026 – Rapport Therapeutics had its price target raised by Guggenheim from $65.00 to $70.00. They now have a “buy” rating on the stock.
• 10/20/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial. They now have a $86.00 price target on the stock.
• 10/20/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 10/20/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.
• 10/20/2026 – Rapport Therapeutics had its price target raised by BTIG Research from $75.00 to $89.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Rapport Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Rapport Therapeutics is now covered by UBS Group. They set a “buy” rating and a $71.00 price target on the stock.
• 10/15/2026 – Rapport Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $50.00 price target on the stock.
• 10/14/2026 – Rapport Therapeutics was upgraded by UBS Group to “strong-buy”.
• 10/6/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 10/5/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 10/5/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 9/23/2026 – Rapport Therapeutics was given a new $80.00 price target by UBS Group.
• 9/23/2026 – Rapport Therapeutics had its “market outperform” rating reaffirmed by Citigroup.
• 9/22/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial.
• 9/16/2026 – Rapport Therapeutics had its price target raised by BTIG Research from $65.00 to $75.00. They now have a “buy” rating on the stock.

Rapport Therapeutics Stock Performance

NASDAQ RAPP opened at $26.07 on Tuesday. The company has a market cap of $1.25 billion, a P/E ratio of -8.22 and a beta of 1.40. The business’s 50 day moving average price is $33.70 and its 200-day moving average price is $35.52. Rapport Therapeutics, Inc. has a fifty-two week low of $22.06 and a fifty-two week high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.36. As a group, equities analysts predict that Rapport Therapeutics, Inc. will post -3.34 EPS for the current year.

Insiders Place Their Bets

In other news, Director Steven M. Paul bought 35,714 shares of Rapport Therapeutics stock in a transaction dated Thursday, October 22nd. The shares were acquired at an average price of $27.28 per share, with a total value of $974,277.92. Following the completion of the purchase, the director owned 77,380 shares in the company, valued at $2,110,926.40. The trade was a 85.71% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director James Healy bought 969,480 shares of the stock in a transaction dated Wednesday, October 28th. The stock was purchased at an average price of $21.00 per share, with a total value of $20,359,080.00. Following the acquisition, the director directly owned 2,815,707 shares in the company, valued at approximately $59,129,847. The trade was a 52.51% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 1,031,174 shares of company stock valued at $22,023,898 and have sold 46,477 shares valued at $1,958,709. Insiders own 12.48% of the company’s stock.

Rapport Therapeutics is a Boston-based biotechnology company developing medicines for neurological and psychiatric disorders. Founded in 2022, the company focuses on small molecules designed to act on mechanisms that regulate the movement and function of proteins in the brain.

Its research platform is intended to identify targets involved in neuronal signaling, including interactions that influence ion channels. Rapport’s pipeline includes RAP-219, an investigational medicine that modulates AMPA receptors and is being developed for focal epilepsy.

The company’s work is centered on discovering and developing treatments for conditions with limited or inadequate therapeutic options.